Do you ever wonder when and where all of this CBD and cannabis testing and research is being facilitated? Who is the authority in CBD testing and research? With hundreds of thousands online informative articles written specifically for CBD and cannabis online, it’s overwhelming to know who to trust and where to look when trying to find evidence that CBD is beneficial.
As of today, Wednesday August 21st 2019; there are currently 12 Clinical trials underway in the United States. Below is a list of the outline of which CBD testing and study is being conducted and where. The list is wide-spread throughout the US. There are also dozens out clinical trials arranged to executed in the near future, completed, temporarily suspended, etc… but this list, again, is the current research underway as you read this.
The conclusion from looking into what types of studies are being conducted revolve primarily around childhood epilepsy & seizures but also include tolerance, use for normal healthy adults, and skincare.
Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome – Kennedy Krieger Institute
Baltimore, Maryland, United States
Cannabidiol (CBD) to 27 Patients (Aged 2 Years – 19 Years) With Drug Resistant Epilepsy – University of Utah School of Medicine
Salt Lake City, Utah, United States
Cannabidiol Treatment in Patients With Early Psychosis -Connecticut Mental Health Center, New Haven, Connecticut, United States
The Effects of Cannabidiol and ∆-9-THC in Humans – VA Connecticut Healthcare System, West Haven, Connecticut, United States
Safety, and Tolerability of Epidiolex In Patients ((Ages 1 – 19 Years) With Intractable Epilepsy – University of Alabama at Birmingham, Birmingham, Alabama, United States
University of Alabama at Birmingham (UAB) Adult CBD Program – 9University of Alabama at Birmingham
Birmingham, Alabama, United States
Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers – Cooper, New York, New York, United States
A Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms – Nicklaus Children’s Hospital
Miami, Florida, United States. Beaumont Children’s Hospital
Royal Oak, Michigan, United States. Akron Children’s Hospital
Akron, Ohio, United States (and 2 more…).
A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With DS or LGS Currently Taking CBD – PANDA Neurology/CIRCA Atlanta, Georgia, United StatesMultiCare Institute for Research & Innovation, Tacoma, Washington, United States
Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7) – Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States. Nationwide Children’s Hospital, Columbus, Ohio, United States. Le Bonheur Children’s Hospital, Memphis, Tennessee, United States. (and 3 more…)
Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7) – Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States. Nationwide Children’s Hospital, Columbus, Ohio, United States. Le Bonheur Children’s Hospital, Memphis, Tennessee, United States. (and 3 more…)
Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris – Applied Research Center of Arkansas
Little Rock, Arkansas, United States. Encino Research Center
Encino, California, United States. Dermatology Specialist, Inc.
Murrieta, California, United States (and 33 more…).